NASDAQ$PROK
ProKidney Corp · Q1 2025 earnings
Q1 2025 earnings · · Before market open · Investor relations
Briefing
ProKidney reported Q1 2025 revenue of $230.0K, a net loss of $16.7M, diluted EPS of $-0.13.
For Q1 2025, ProKidney reported Revenue was $230.0K, net loss was $16.7M, diluted EPS was $-0.13. Management discusses segment trends, liquidity, and outlook in the quarterly filing.
- Revenue $230.0K for Q1 2025.
- Net loss $16.7M.
- Diluted EPS $-0.13.
Headline financials
Revenue & EPS history
ProKidney · Revenue · Quarterly
$230K
Forward guidance
Outlook emphasizes clinical milestones, liquidity runway, and cost discipline.
Tailwinds
- Pipeline readouts and partnership economics.
- Cash balance supports near-term development plans.
Headwinds
- Operating losses and trial risk until commercialization.
- Financing markets and competition affect funding costs.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 15 quarterly earnings reports · overlaid with Q1 2025
-2.4%
Avg return
Earnings day
-3.0%
Avg return
5 days after
+2.6%
Avg return
30 days after
25%
4 / 16 earnings
Positive
+18.0%
Q1 2024
Best reaction
-13.1%
Q3 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -2.3% | -1.2% | -4.7% | |
| Q4 2025 | -4.0% | -8.9% | +2.3% | |
| Q3 2025 | -8.8% | -16.6% | -24.9% | |
| Q2 2025 | -0.9% | +4.7% | +32.2% | |
| Q1 2025 | -6.0% | -9.3% | -1.4% | |
| Q4 2024 | -6.8% | -7.7% | -23.9% | |
| Q3 2024 | -3.7% | -21.2% | -12.6% | |
| Q2 2024 | -0.5% | +9.1% | +11.5% | |
| Q1 2024 | +18.0% | +50.2% | +22.2% | |
| Q4 2023 | -4.1% | +8.9% | +39.7% | |
| Q3 2023 | -13.1% | -24.4% | +20.0% | |
| Q2 2023 | +0.4% | -14.5% | -37.5% | |
| Q1 2023 | +1.2% | +8.1% | +34.0% | |
| Q4 2022 | -9.8% | -12.9% | -24.6% | |
| Q3 2022 | -4.7% | -14.8% | -23.6% | |
| Q2 2022 | +7.3% | +2.7% | +32.6% |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro